Exponent, Inc. reports Q1 fiscal 2026 results tonight — and the week's most telling story isn't what's happening in the options market, but the quiet repositioning underway in short interest, the CEO's repeated selling, and a Street that still believes the stock is worth considerably more than $66.
Short sellers pulled back into the print. SI dropped 3.7% over the week to 6.3% of free float, reversing some of the surge that added nearly 17% to the short position across April. The April build — from roughly 2.9 million shares short in early April to 3.3 million mid-month — was notable. It has now partially unwound, but at 3.2 million shares (per FINRA's April 15 settlement figure) the position is still larger than where the month began. Days to cover runs at 7.2, meaning any squeeze would unfold slowly. The borrow market is relaxed: availability is high and the cost to borrow is just 0.47%, barely changed from a month ago despite the intra-month spike in short positioning. Nothing in the lending market signals distress.
Options positioning leans distinctly bullish — almost unusually so. The put/call ratio is sitting at 0.02, just above its 52-week low of 0.02 and meaningfully below its 20-day mean of 0.023. Call buyers have dominated the options tape for weeks, with the z-score slightly negative. That's not a hedging setup; it reads as speculative positioning into tonight's number. The sharp contrast between options (bullish) and the month's short-interest build (bearish) is the clearest tension in the data heading into the close.
The Street remains constructive but cautiously so. JP Morgan, the most recent voice, trimmed its target from $100 to $95 in late March while holding its Overweight rating. UBS keeps a Neutral with an $81 target. The mean target across the coverage universe is $90, implying about 36% upside to the current price of $66.18 — a gap that reflects genuine disagreement about whether demand for Exponent's litigation support and failure-analysis consulting holds up in a slowing economy. The PE multiple is 26x, EV/EBITDA around 18x on trailing numbers, which is reasonable for a capital-light services firm growing at a steady pace but leaves little room for a revenue miss. Analyst consensus leans positive (the analyst recommendation differential factor scores at 48, roughly mid-range), and the dividend score ranks at the 96th percentile — Exponent has historically returned cash reliably.
The insider picture complicates the narrative. CEO Catherine Corrigan sold nearly $900,000 worth of stock across March and April in a series of transactions, all near the $67–$70 price level. The individual trade significance scores are low (all rated 1/10), and the sales follow a predictable scheduled-plan pattern. Still, the net insider position over the past 90 days is positive at $2.6 million in value terms and 37,378 net shares — the bulk of that being equity awards rather than open-market purchases. No insider has been a buyer on the open market in the recent filing record. At a stock price now roughly 6% below those CEO sale prices, the sells look less like conviction and more like routine diversification, but they are worth noting.
Among correlated peers, CRAI was nearly flat on the week while LDOS fell 3.2% — a range that brackets EXPO's own 2% weekly decline. TNET bucked the group with a 5.2% gain, a reminder that the professional services basket isn't trading as a monolith right now. The one data point to watch after tonight's print is whether the April short-interest build proves prescient or gets unwound: a strong Q1 beat and in-line guidance would squeeze a position that has grown meaningfully in a matter of weeks.
See the live data behind this article on ORTEX.
Open EXPO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
